Using this mouse primary HCC model, we aimed to observe the efficacy of a FAK inhibitor (VS4718) in combination with an anti-PD1 antibody for the treatment of HCC and investigate the related mechanism. Here, PDCD1 is linked to hepatocellular carcinoma.